Authors:
TAHVANAINEN E
SYVANNE M
FRICK MH
MURTOMAKIREPO S
ANTIKAINEN M
KESANIEMI YA
KAUMA H
PASTERNAK A
TASKINEN MR
EHNHOLM C
Citation: E. Tahvanainen et al., ASSOCIATION OF VARIATION IN HEPATIC LIPASE ACTIVITY WITH PROMOTER VARIATION IN THE HEPATIC LIPASE GENE, The Journal of clinical investigation, 101(5), 1998, pp. 956-960
Authors:
HUMPHRIES SE
LUONG LA
TALMUD PJ
FRICK MH
KESANIEMI YA
PASTERNACK A
TASKINEN MR
SYVANNE M
Citation: Se. Humphries et al., THE 5A 6A POLYMORPHISM IN THE PROMOTER OF THE STROMELYSIN-1 (MMP-3) GENE PREDICTS PROGRESSION OF ANGIOGRAPHICALLY DETERMINED CORONARY-ARTERY DISEASE IN MEN IN THE LOCAT GEMFIBROZIL STUDY/, Atherosclerosis (Amsterdam), 139(1), 1998, pp. 49-56
Authors:
SYVANNE M
NIEMINEN MS
FRICK MH
KAUMA H
MAJAHALME S
VIRTANEN V
KESANIEMI YA
PASTERNACK A
EHNHOLM C
TASKINEN MR
Citation: M. Syvanne et al., ASSOCIATIONS BETWEEN LIPOPROTEINS AND THE PROGRESSION OF CORONARY ANDVEIN-GRAFT ATHEROSCLEROSIS IN A CONTROLLED TRIAL WITH GEMFIBROZIL IN MEN WITH LOW BASE-LINE LEVELS OF HDL CHOLESTEROL, Circulation, 98(19), 1998, pp. 1993-1999
Authors:
SYVANNE M
TASKINEN MR
NIEMINEN MS
MANNINEN V
KESANIEMI YA
PASTERNACK A
NAWROCKI JW
HABER H
FRICK MH
Citation: M. Syvanne et al., A STUDY TO DETERMINE THE RESPONSE OF CORONARY ATHEROSCLEROSIS TO RAISING LOW HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL WITH A FIBRIC-ACID DERIVATIVE IN MEN AFTER CORONARY-BYPASS SURGERY - THE RATIONALE, DESIGN, ANDBASE-LINE CHARACTERISTICS OF THE LOCAT STUDY, Controlled clinical trials, 18(1), 1997, pp. 93-119
Authors:
FRICK MH
SYVANNE M
NIEMINEN MS
KAUMA H
MAJAHALME S
VIRTANEN V
KESANIEMI A
PASTERNACK A
TASKINEN MR
Citation: Mh. Frick et al., PREVENTION OF THE ANGIOGRAPHIC PROGRESSION OF CORONARY AND VEIN-GRAFTATHEROSCLEROSIS BY GEMFIBROZIL AFTER CORONARY-BYPASS SURGERY IN MEN WITH LOW-LEVELS OF HDL CHOLESTEROL, Circulation, 96(7), 1997, pp. 2137-2143
Authors:
ANTIKAINEN M
MURTOMAKI S
SYVANNE M
PAHLMAN R
TAHVANAINEN E
JAUHIAINEN M
FRICK MH
EHNHOLM C
Citation: M. Antikainen et al., THE GLN-ARG191 POLYMORPHISM OF THE HUMAN PARAOXONASE GENE (HUMPONA) IS NOT ASSOCIATED WITH THE RISK OF CORONARY-ARTERY DISEASE IN FINNS, The Journal of clinical investigation, 98(4), 1996, pp. 883-885
Authors:
MANTTARI M
TENKANEN L
MANNINEN V
ALIKOSKI T
FRICK MH
Citation: M. Manttari et al., ANTIHYPERTENSIVE THERAPY IN DYSLIPIDEMIC MEN - EFFECTS ON CORONARY HEART-DISEASE INCIDENCE AND TOTAL MORTALITY, Hypertension, 25(1), 1995, pp. 47-52
Citation: Mh. Frick et al., CALCIUM SENSITIZATION VIA TROPONIN-C - A NEW APPROACH FOR THE TREATMENT OF HEART-FAILURE - PROCEEDINGS OF AN INTERNATIONAL-SYMPOSIUM IN ASSOCIATION WITH THE JOINT XIITH WORLD CONGRESS OF CARDIOLOGY AND XVITH CONGRESS OF THE EUROPEAN-SOCIETY-OF-CARDIOLOGY, SEPTEMBER 10, 1994, BERLIN, GERMANY - PREFACE, Journal of cardiovascular pharmacology, 26, 1995, pp. 5-6
Authors:
HUTTUNEN JK
HEINONEN P
MANNINEN V
KOSKINEN P
HAKULINEN T
TEPPO L
MANTTARI M
FRICK MH
Citation: Jk. Huttunen et al., THE HELSINKI-HEART-STUDY - AN 8.5-YEAR SAFETY AND MORTALITY FOLLOW-UP, Journal of internal medicine, 235(1), 1994, pp. 31-39
Authors:
HEINONEN OP
HUTTUNEN JK
MANNINEN V
MANTTARI M
KOSKINEN P
TENKANEN L
FRICK MH
Citation: Op. Heinonen et al., THE HELSINKI-HEART-STUDY - CORONARY HEART-DISEASE INCIDENCE DURING ANEXTENDED FOLLOW-UP, Journal of internal medicine, 235(1), 1994, pp. 41-49
Authors:
REMME WJ
KRAYENBUHL HP
BAUMANN G
FRICK MH
HAEHL M
NEHMIZ G
BAIKER W
Citation: Wj. Remme et al., LONG-TERM EFFICACY AND SAFETY OF PIMOBENDAN IN MODERATE HEART-FAILURE- A DOUBLE-BLIND PARALLEL 6-MONTH COMPARISON WITH ENALAPRIL, European heart journal, 15(7), 1994, pp. 947-956
Authors:
HAUTANEN A
MANTTARI M
MANNINEN V
TENKANEN L
HUTTUNEN JK
FRICK MH
ADLERCREUTZ H
Citation: A. Hautanen et al., ADRENAL ANDROGENS AND TESTOSTERONE AS CORONARY RISK-FACTORS IN THE HELSINKI HEART-STUDY, Atherosclerosis, 105(2), 1994, pp. 191-200
Authors:
HAUTANEN A
MANTTARI M
KUPARI M
SARNA S
MANNINEN V
FRICK MH
ADLERCREUTZ H
Citation: A. Hautanen et al., CIGARETTE-SMOKING IS ASSOCIATED WITH ELEVATED ADRENAL ANDROGEN RESPONSE TO ADRENOCORTICOTROPIN, Journal of steroid biochemistry and molecular biology, 46(2), 1993, pp. 245-251
Citation: Mh. Frick, CHOLESTEROL AND CORONARIES - A CITATION-CLASSIC COMMENTARY ON HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE BY FRICK,M.H., ELO,O., HAAPA,K., HEINONEN,O.P., HEINSALMI,P., HELO,P., HUTTUNEN,J.K., KAITANIEMI,P., KOSKINEN,P., MANNINEN,V., MAENPAA,H., MALKONEN,M., MANTTARI,M., NOROLA,S., PASTERNACK,A., PIKKARAINEN,J., ROMO,M.,, Current contents. Clinical medicine, (38), 1993, pp. 8-8
Citation: V. Valtonen et al., 10TH PAAVO-NURMI-SYMPOSIUM - ROLE OF INFECTION AND IN FLAMMATION IN VASCULAR-DISEASE - 27-29 AUGUST 1992, HELSINKI, FINLAND - FOREWORD, European heart journal, 14, 1993, pp. 1-1
Authors:
MANTTARI M
MANNINEN V
HUTTUNEN JK
HEINONEN OP
FRICK MH
Citation: M. Manttari et al., SERUM FERRITIN AND CERULOPLASMIN AS CORONARY RISK-FACTORS - A NESTED CASE-CONTROL STUDY IN THE HELSINKI HEART-STUDY POPULATION, Circulation, 88(4), 1993, pp. 70-70